NCT02301416View on ClinicalTrials.gov

Qsymia as an Adjunct to Surgical Therapy in the Superobese

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 27, 2018

Study Completion Date

June 27, 2018

Conditions
ObesityMetabolic SurgeryWeight LossBariatric Surgery Procedures
Interventions
DRUG

Phentermine/topiramate

Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.

OTHER

low calorie diet

The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.

Trial Locations (1)

27157

Wake Forest Baptist Health, Winston-Salem

All Listed Sponsors
collaborator

VIVUS LLC

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT02301416 - Qsymia as an Adjunct to Surgical Therapy in the Superobese | Biotech Hunter | Biotech Hunter